LRRK2 and Parkinson disease: Indeed, a recent study using LRRK2 antisense oligonucleotides (ASOs) has shown that decreased endogenous levels of LRRK2 reduces α-synuclein inclusion in order to be a potential therapeutic strategy for preventing PD [251].